Alternus Energy Group (ALT:ASX) Annual Reports & Investor Relations Material

Overview

Altimmune Inc., a clinical stage biopharmaceutical company, is paving the way for innovative treatments for obesity and liver diseases. The Maryland-based company's primary focus is on its GLP-1/glucagon dual receptor agonist, Pemvidutide. Currently in Phase 2 trials, this candidate aims to combat obesity and non-alcoholic steatohepatitis. Altimmune is also making strides in immunotherapeutic products with its Phase 2 clinical trial candidate, HepTcell - designed for patients with chronic hepatitis B infections. Founded in 1997 under the name Vaxin Inc., Altimmune changed its name in September 2015, and its headquarters are located in Gaithersburg, Maryland.

Frequently Asked Questions

What is Alternus Energy Group's ticker?

Alternus Energy Group's ticker is ALT

What exchange is Alternus Energy Group traded on?

The company's shares trade on the ASX stock exchange

Where are Alternus Energy Group's headquarters?

They are based in Brisbane, Australia

How many employees does Alternus Energy Group have?

There are 1-10 employees working at Alternus Energy Group

What is Alternus Energy Group's website?

It is alternusenergy.com/about

What type of sector is Alternus Energy Group?

Alternus Energy Group is in the Healthcare sector